Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionT. Rowe Price Index Trust, Inc. - T. Rowe Price Small-Cap Index Fund
Latest Disclosed Ownership13,915 shares
Latest Disclosed Value $ 344,535
T. Rowe Price Index Trust, Inc. - T. Rowe Price Small-Cap Index Fund reports 13.43% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 28, 2026 - T. Rowe Price Index Trust, Inc. - T. Rowe Price Small-Cap Index Fund filed a NPORT-P form disclosing ownership of 13,915 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $344,535 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 26, 2026 disclosing 12,268 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 13.43% during the quarter. The current value of the position is $438,183 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-28 2026-03-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 13,915 1,647 13.43 345 20.28 0.0972
2026-02-26 2025-12-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 12,268 847 7.42 286 27.68 0.0928
2025-11-25 2025-09-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 11,421 572 5.27 225 -4.68 0.0789
2025-08-26 2025-06-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 10,849 1,374 14.50 235 2.62 0.0983
2025-05-30 2025-03-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 9,475 927 10.84 230 28.65 0.1126
2025-02-27 2024-12-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 8,548 621 7.83 178 13.38 0.0865
2024-11-26 2024-09-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 7,927 716 9.93 158 41.44 0.0824
2024-08-27 2024-06-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 7,211 159 2.25 112 -0.89 0.0666
2024-05-29 2024-03-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 7,052 1,284 22.26 112 16.67 0.0658
2024-02-26 2023-12-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 5,768 418 7.81 97 54.84 0.0654
2023-11-28 2023-09-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 5,350 632 13.40 63 -1.59 0.0519
2023-08-28 2023-06-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 4,718 268 6.02 63 -13.70 0.0533
2023-05-26 2023-03-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 4,450 212 5.00 74 -6.41 0.0697
2023-02-24 2022-12-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 4,238 429 11.26 79 62.50 0.0810
2022-11-25 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,809 85 2.28 49 84.62 0.0557
2022-08-24 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 3,724 300 8.76 26 -7.14 0.0296
2022-05-27 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,424 400 13.23 28 40.00 0.0289
2022-02-24 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,024 208 7.39 20 42.86 0.0224
2021-11-24 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,816 0 0.00 15 -12.50 0.0183
2021-08-25 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,816 1,859 194.25 16 300.00 0.0193
2021-05-26 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 957 685 251.84 4 -75.00 0.0158
2021-02-24 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 272 0 0.00 1 -100.00 0.0125
2020-11-25 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 272 0 0.00 1 -100.00 0.0141
2020-08-24 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 272 17 6.67 1 0.0231
2020-05-26 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 255 0 0.00 1 -100.00 0.0226
2020-02-25 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 255 0 0.00 1 -100.00 0.0157
2019-11-25 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 255 255 1 0.0233
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.